Endometrial cancer is the most common gynecological malignancy. Although it can often be diagnosed at an early stage and managed successfully with surgery, there are currently no effective treatments for advanced and recurrent disease, resulting in substantial mortality. While the efficacy of treatment and patient survival for other hormone-responsive cancers, such as breast and prostate, continue to improve, the incidence and mortality remains stubbornly high for endometrial cancer, indicating an urgent need for a better understanding of the disease and translation of research from bench to bedside.

We invite investigators worldwide to contribute original articles and reviews that contribute to the advancement of endometrial cancer research. Investigators are particularly encouraged to report the state of research in endometrial cancer, progress in the understanding of basic molecular mechanisms of this disease, and the development of novel biomarkers and therapeutic agents. Potential topics include, but are not limited to:

• Molecular and cellular mechanisms of carcinogenesis and tumor progression
• Molecular profiling for tumor classification
• Biomarker development for improved patient outcomes and drug efficacy
• Mechanism of the development of drug resistance and treatment failure
• Novel models in endometrial cancer research

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ogi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/author/submit/journals/ogi/mcbt/ according to the following timetable: